# Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

> **NCT00551330** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 111 (actual)

## Conditions studied

- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Vicriviroc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00551330
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-05
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551330, "Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00551330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*